Inhaled pharmaceuticals have a long history, dating back to ancient times when treatments such as those documented in the Ebers Papyrus, an Egyptian medical text from around 1550 BC, were used to alleviate asthma symptoms. Progressing into the modern age, the U.S. FDA approved inhaled epinephrine for asthma in 1929. This milestone marked a new era in the field, which was further bolstered by the advent of pressurised metered-dose inhalers (MDIs) in the 1950s and dry powder inhalers (DPIs) in the 1960s.
Today, companies like Broughton, a global scientific consultancy-based Contract Research Organisation (CRO), stand on this historical foundation as they innovate in the realm of inhaled pharmaceuticals. Broughton has recently introduced a state-of-the-art inhalation testing service that leverages their in-house laboratory testing facilities, analytical testing expertise, and an in-depth understanding of aerosol and inhalation science to provide a comprehensive solution for testing, consulting, and compliance requirements.